Combining BRAF, MEK and EGFR Inhibition in mCRC

Video

Experts review the scientific rationale for combining BRAF, MEK and EGFR inhibition in BRAF-mutated mCRC; a strategy tested in such settings as the ANCHOR and BEACON trials.

Related Videos
Milind Javle, MD; Rachna Shroff, MD, MS, FASCO
Milind Javle, MD; Rachna Shroff, MD, MS, FASCO
Milind Javle, MD; Rachna Shroff, MD, MS, FASCO
Milind Javle, MD; and Rachna Shroff, MD, MS, FASCO
 Milind Javle, MD, and Rachna Shroff, MD, MS, FASCO
Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; Steven Scott West
Amin Nassar, MD
Kara N. Maxwell, MD, PhD